¡°ºÈ¾Æ²ÅÉ˸Σ¿£¿£¿£¿£¿£¿£¿£¿Ö¬·¾¸ÎÊÇÅÖÈ˵ÄרÀû£¿£¿£¿£¿£¿£¿£¿£¿Ã»Ö¢×´¾ÍÊǸÎÔ࿵½¡£¿£¿£¿£¿£¿£¿£¿£¿¡±ÕâЩÈö²¥Éõ¹ãµÄÈÏÖªÎóÇø£¬£¬£¬£¬£¬£¬ÕýÔÚÈÃÐí¶àÈ˵ĸÎÔàÇÄÇÄ¡°ÁÁºìµÆ¡±¡£¡£¡£¡£¡£¡£¡£¡£½ñÄê3ÔÂ18ÈÕ£¬£¬£¬£¬£¬£¬ÊǵÚ26¸öÌìϰ®¸ÎÈÕ£¬£¬£¬£¬£¬£¬Ðû´«Ö÷ÌâÊÇ¡°×èÖ¹¸ÎÓ²»¯£¬£¬£¬£¬£¬£¬Ô¶Àë¸Î°©¡±¡£¡£¡£¡£¡£¡£¡£¡£
ÄãµÄ¸ÎÔ࣬£¬£¬£¬£¬£¬¿ÉÄܱÈÏëÏóÖиü¡°Å³Èõ¡±
¸ÎÔà×÷ΪÈËÌå¡°´úлÖÐÊࡱ£¬£¬£¬£¬£¬£¬¼ÓÈë¶àÖÖÉú»¯·´Ó¦Àú³Ì£¬£¬£¬£¬£¬£¬°üÀ¨µ÷Àí̼ˮ»¯ºÏÎï¡¢Ö¬ÀàºÍÂѰ×ÖÊ´úл£»£»£»£»£»£»£»ºÏ³ÉÒªº¦ÂѰ×ÖÊ£¬£¬£¬£¬£¬£¬°üÀ¨°×ÂѰס¢ÄýѪÒò×ÓºÍøµÈ£»£»£»£»£»£»£»»¹³äµ±¹ýÂËÆ÷£¬£¬£¬£¬£¬£¬ÔÚ¾»»¯ºÍɨ³ýѪҺÖеķÏÎï¼°¶¾ËØ£¨Ò©Îï¡¢ÍâÀ´ÎïÖÊ£©·½ÃæÆð×ÅÒªº¦×÷ÓÃ[1-2]¡£¡£¡£¡£¡£¡£¡£¡£
¿ÉÊÇ£¬£¬£¬£¬£¬£¬ËüÈ´ºÍÉöÔàÒ»ÑùÊÇ¡°Ä¬È»µÄÆ÷¹Ù¡±¡ª¡ªÑо¿Ö¸³ö£¬£¬£¬£¬£¬£¬¸ÎÔàȱ·¦Í´¾õÉñ¾£¬£¬£¬£¬£¬£¬30%¡«40%µÄ¹¦Ð§±£´æ¼´¿Éά³ÖÕý³£ÔËת£¬£¬£¬£¬£¬£¬ÇáÖжÈËðÉËÏÕЩÎÞÖ¢×´[3]¡£¡£¡£¡£¡£¡£¡£¡£ÎÒ¹úÂýÐԸβ¡»¼ÕßÕ¼±È¸ß£¬£¬£¬£¬£¬£¬ÆäÖУ¬£¬£¬£¬£¬£¬ÒÔÖ¬·¾¸Î¡¢²¡¶¾ÐÔ¸ÎÑס¢Ò©ÎïÐÔ¸ÎËðÉËΪÈý´óÖ÷Òª²¡Òò¡£¡£¡£¡£¡£¡£¡£¡£

×èÖ¹2018Ä꣬£¬£¬£¬£¬£¬ÎÒ¹ú·Ç¾Æ¾«ÐÔÖ¬·¾¸Î»¼²¡ÂÊÒÑ´ï32.9%[4]£¬£¬£¬£¬£¬£¬Æ½¾ùÿ3¸ö³ÉÄêÈËÖоÍÓÐ1ÈË»¼²¡£¬£¬£¬£¬£¬£¬ÇÒÄê·¢²¡ÂʾÓÈ«ÇòÊ×λ£»£»£»£»£»£»£»2024ÄêWHO¸ÎÑ×±¨¸æÖУ¬£¬£¬£¬£¬£¬2022ÄêÈ«ÇòHBV£¨ÒÒÐ͸ÎÑײ¡¶¾£©Ñ¬È¾ÂÊΪ3.2%£¨2.54ÒÚÀý£©£¬£¬£¬£¬£¬£¬ÖйúÂýÐÔÒÒÐͲ¡¶¾ÐÔ¸ÎÑ×Ê¢ÐÐÂÊԼΪ5.6%[5]£¬£¬£¬£¬£¬£¬Õ¼È«ÇòµÄ31.5%£¬£¬£¬£¬£¬£¬Õ¼ÑÇÌ«µØÇøµÄ82.2%¡£¡£¡£¡£¡£¡£¡£¡£
СÐÄ£¡Ô¶ÀëÕâÎå¸ö¡°»¤¸ÎÎóÇø¡±
ÎóÇø1 ²»ºÈ¾Æ¾Í²»»áµÃ¸Î²¡
2020ÄêÖйúNAFLD£¨·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡£¡£¡£¡£¡£¡£¡£¡£©µÄÊ¢Ðв¡Ñ§Ñо¿ÏÔʾ£¬£¬£¬£¬£¬£¬2018ÄêÎÒ¹úÖ¬·¾¸Î»¼ÕßÖУ¬£¬£¬£¬£¬£¬·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÕ¼±È¸ß´ï32.9%£¬£¬£¬£¬£¬£¬ÇÒ·¢²¡ÂÊËæÊ±¼äÏÔÖøÉÏÉý[6]¡£¡£¡£¡£¡£¡£¡£¡£
´úлÏà¹Ø£¨·Ç¾Æ¾«ÐÔ£©Ö¬·¾ÐԸβ¡·ÀÖÎÖ¸ÄÏ£¨2024Äê°æ£©Ö¸³ö£¬£¬£¬£¬£¬£¬¸ßÌÇÒûʳ¡¢¾Ã×ø¡¢ÒȵºËضԿ¹Êǵ¼Ö·Ǿƾ«ÐÔÖ¬·¾¸ÎµÄ½¹µãÓÕÒò£¬£¬£¬£¬£¬£¬×ÝÈ»µÎ¾Æ²»Õ´£¬£¬£¬£¬£¬£¬ºã¾ÃºÈÄ̲衢³ÔÌðµãÒ²¿ÉÄÜÒý·¢¸Îϸ°ûÖ¬·¾±äÐÔ[7]¡£¡£¡£¡£¡£¡£¡£¡£
ÎóÇø2 ÊÝ£¬£¬£¬£¬£¬£¬¾ÍÓëÖ¬·¾¸ÎÎÞÔµ
ÑÇÖÞÈËÌåÖʸüÒ×·ºÆð¡°´úлÐÔ·ÊÅÖ¡±[8]¡ª¡ª×ÝÈ»BMI£¨ÉíÌåÖÊÁ¿Ö¸Êý£©Õý³££¬£¬£¬£¬£¬£¬Ð¡¶Ç×ÓÍ»³ö¡¢¼¡ÈâÁ¿ÉÙµÄÈË£¬£¬£¬£¬£¬£¬ÄÚÔàÖ¬·¾º¬Á¿Ò²¿ÉÄܳ¬±ê¡£¡£¡£¡£¡£¡£¡£¡£Ò»ÏîÄÉÈëÁË6086Ãû6¡«18ËêÖйú¶ùͯµÄÑо¿[9]£¬£¬£¬£¬£¬£¬Í¨¹ý±ÈÕÕʵÑé·¢Ã÷£¬£¬£¬£¬£¬£¬»¼ÓзÊÅֺͷǾƾ«ÐÔÖ¬·¾ÐԸβ¡µÄ¶ùͯ£¬£¬£¬£¬£¬£¬¿ÉÄÜÃæÁÙÏÔÖøÔöÌíµÄ´úлÒ쳣Σº¦¡£¡£¡£¡£¡£¡£¡£¡£×ÝÈ»ÊÇûÓзÊÅֵĶùͯ£¬£¬£¬£¬£¬£¬·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÒ²Óë´úл״̬¶ñ»¯µÄΣº¦ÔöÌíÓйء£¡£¡£¡£¡£¡£¡£¡£¸üÒªº¦µÄÊÇ£¬£¬£¬£¬£¬£¬ÑÇÖÞÈËȺ»ùÒò×éÖÐPNPLA3Σº¦»ùÒòЯ´øÂʸߴï40.9%£¬£¬£¬£¬£¬£¬¶Ô·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄÒ׸ÐÐÔ¸ü¸ß£¬£¬£¬£¬£¬£¬ÌìÉú¸üÒ×»¼Ö¬·¾¸Î[10]¡£¡£¡£¡£¡£¡£¡£¡£
ÎóÇø3 û֢״¾ÍÊǸÎÔ࿵½¡
WebMD[11]Ö¸³ö£¬£¬£¬£¬£¬£¬ÔçÆÚ¸Î²¡¿ÉÄܽöÌåÏÖΪƣÀÍ¡¢Ê³Óû²î¡¢Ð¡±ã·¢»Æ£¬£¬£¬£¬£¬£¬ÕâЩ֢״³£±»ÎóÒÔΪÊÇ¡°°¾Ò¹¡¢Éϻ𡱡£¡£¡£¡£¡£¡£¡£¡£Ò»ÏîÕë¶ÔÌìϵĴóÐÍǰհÐÔÑо¿Êý¾ÝÏÔʾ£¬£¬£¬£¬£¬£¬44.4%µÄÖ¬·¾¸Î»¼ÕßÔÚÌå¼ìÖÐÎÞÒâ·¢Ã÷£¬£¬£¬£¬£¬£¬ÆäÖÐ10.6%ÒÑÉú³¤ÎªÖضÈÖ¬·¾¸Î£¬£¬£¬£¬£¬£¬2.9%·ºÆð¸ÎÏËά»¯£¬£¬£¬£¬£¬£¬0.9%·ºÆð¸ÎÓ²»¯[12]¡£¡£¡£¡£¡£¡£¡£¡£
ÎóÇø4 ¸Î¹¦Ð§Ö¸±êÕý³£¾Í¡°ÍòÊ´󼪡±
¸Î¹¦Ð§Ïà¹ØÖ¸±êÕý³££¬£¬£¬£¬£¬£¬²»´ú±í¸ÎÔàÎÞËðÉË¡£¡£¡£¡£¡£¡£¡£¡£2023Äê¡¶ÉúÃü¿ÆÑ§¡·ÔÓÖ¾¿¯·¢µÄÏà¹ØÑо¿Åú×¢£¬£¬£¬£¬£¬£¬²¿·ÖÖ¬·¾¸Î»¼Õ߸ÎøˮƽÕý³££¬£¬£¬£¬£¬£¬µ«¸ÎÔ൯ÐÔ¼ì²âÒÑÌáÐÑÏËά»¯[13]£»£»£»£»£»£»£»¶ø¸ÎÓ²»¯»¼ÕßÒò¸Îϸ°û´ó×Ú»µËÀ£¬£¬£¬£¬£¬£¬¸Îø·´¶ø¿ÉÄÜÇá¶ÈÉý¸ß[14]¡£¡£¡£¡£¡£¡£¡£¡£
ÎóÇø5 Ö¬·¾¸Î²»±ØÖΣ¬£¬£¬£¬£¬£¬¼õ·Ê¾ÍÐÐ
¼õ·ÊÊÇ»ù´¡£¬£¬£¬£¬£¬£¬µ«Ðè¿ÆÑ§¸ÉÔ¤¡£¡£¡£¡£¡£¡£¡£¡£Ïà¹ØÎÄÏ×Ö¸³ö£ºÌåÖØïÔÌ5%¿É¸ÄÉÆ¸Îϸ°ûÖ¬·¾±äÐÔ£¬£¬£¬£¬£¬£¬ïÔÌ10%ÒÔÉϲſÉÄÜÄæ×ªÔçÆÚ¸ÎÏËά»¯[15-16]£¬£¬£¬£¬£¬£¬Ã¤Ä¿¼õ·Ê¿ÉÄܼÓÖØ¸ÎËðÉË¡£¡£¡£¡£¡£¡£¡£¡£¸üÖ÷ÒªµÄÊÇ£¬£¬£¬£¬£¬£¬Ö¬·¾¸Î¿ÉÄÜÅãͬѪÌÇ¡¢ÑªÖ¬Òì³££¬£¬£¬£¬£¬£¬Ðèͨ¹ýרҵ¼ì²âÃ÷È·²¡Òò¡£¡£¡£¡£¡£¡£¡£¡£

ȨÍþ¹²Ê¶ÍƼö£ºÕâÁùÀàÈËȺӦ°´ÆÚ¼ì²é
¡¶ÂýÐԸβ¡É¸²éÓë¹ÜÀíÖйúר¼Ò¹²Ê¶£¨2024°æ£©¡·ÍƼö£¬£¬£¬£¬£¬£¬ÒÔÏÂÈËȺÿ6¡«12¸öÔ¾ÙÐÐÒ»´Î¸ÎÔàרÏî¼ì²â£º
1. ÌÇÄò²¡¡¢¸ßѪѹ¡¢¸ßѪ֬»¼Õߣ¨´úл×ÛºÏÕ÷ÈËȺ¸Î²¡Î£º¦ÔöÌí3¡«5±¶£©
2. ·ÊÅÖ£¨BMI¡Ý28£©¡¢¾Ã×ø¡¢ºã¾Ã¸ßÌǸßÖ¬ÒûʳÈËȺ
3. ÓиÎÑ×¼Ò×åÊ·¡¢¸ÎÓ²»¯¡¢¸Î°©¼Ò×åÊ·Õß
4. ºã¾Ã·þÓÃÖвÝÒ©¡¢¿¹½áºËÒ©¡¢½µÖ¬Ò©µÈ¸ÎËðÉËΣº¦Ò©ÎïÕß
5. 65ËêÒÔÉÏÍíÄêÈË£¨¸Î´úл¹¦Ð§Ï½µ£¬£¬£¬£¬£¬£¬»¼²¡Âʳ¬25%£©
6. Ôø»¼¼±ÐÔ¸ÎËðÉË¡¢²¡¶¾ÐÔ¸ÎÑ×Õß
¹ú¼Ê¸Î²¡Ñ§»á£¨IASL£©¡¶·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡ÕïÁÆÖ¸ÄÏ£¨2023£©¡·Ç¿µ÷£ºÔçÆÚɸ²é¿Éʹ¸Î²¡Ï£ÍûΣº¦½µµÍ60%£¬£¬£¬£¬£¬£¬¸Î°©±¬·¢ÂÊϽµ45%£¬£¬£¬£¬£¬£¬¶ø´í¹ý×î¼Ñ¸ÉÔ¤ÆÚµÄ¸ÎÓ²»¯»¼Õߣ¬£¬£¬£¬£¬£¬5ÄêÉúÑÄÂʽöΪ50%¡£¡£¡£¡£¡£¡£¡£¡£
¿ÆÑ§»¤¸Î£¬£¬£¬£¬£¬£¬´Ó¡°Ö¸Äϼ¶¡±¼ì²â×îÏÈ
פ×ãÁÙ´²ÕïÁÆÐèÇ󣬣¬£¬£¬£¬£¬ÒÀÍС¶Å·ÖÞ¸ÎÔàÑо¿Ñ§»áÁÙ´²Êµ¼ùÖ¸ÄÏ¡·¼°¡¶¸ÎÓ²»¯ÁÙ´²ÕïÖιÜÀíÖ¸ÄÏ£¨2025 °æ£©¡·[17]µÈÖ¸ÄÏ¡¢¹²Ê¶£¬£¬£¬£¬£¬£¬2121·Ç·²¿ÉÌṩÂýÐԸβ¡ÔçÆÚɸ²éÏîÄ¿£¬£¬£¬£¬£¬£¬ÊµÏÖ¡°¾«×¼¼ì²â+¿ÆÑ§½â¶Á¡±£¬£¬£¬£¬£¬£¬ÎªÁÙ´²Ìṩ¸öÐÔ»¯¸ÉÔ¤½¨Òé¡£¡£¡£¡£¡£¡£¡£¡£
Èýά¼ì²âϵͳ£¬£¬£¬£¬£¬£¬ÁýÕÖ½¹µãΣº¦µã
1. »ù´¡Ö¸±ê£º¸Î¹¦Ð§ÎåÏALT/AST/ µ¨ºìËØµÈ£©+Ѫ֬/ѪÌÇ£¬£¬£¬£¬£¬£¬ÅŲé´úлÐÔ¸ÎËðÉË£»£»£»£»£»£»£»
2. ÌØÉ«Ö¸±ê£º¸ÎÏËά»¯ËÄÏ£¬£¬£¬£¬£¬ÆÀ¹ÀÏËά»¯Î£º¦£¨¸ÎÓ²»¯Ô¤¾¯£©£»£»£»£»£»£»£»ÌÇȱʧÐÔתÌúÂѰ×(CDT)£¬£¬£¬£¬£¬£¬ÆÀ¹À¾Æ¾«ÐԸβ¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»
3. ²¡Òòɸ²é£º¼×¸Î/ÒÒ¸Î/±û¸Î¿¹Ìå¼ì²â£¬£¬£¬£¬£¬£¬É¨³ý²¡¶¾ÐÔ¸ÎÑ×£»£»£»£»£»£»£»Ò©ÎïÐÔ¸ÎËðÉ˱ê¼ÇÎ£¬£¬£¬£¬£¬ÊÊÅäºã¾ÃÓÃÒ©ÈËȺ¡£¡£¡£¡£¡£¡£¡£¡£
Èý´ó½¹µãÓÅÊÆ£¬£¬£¬£¬£¬£¬Èüì²â¸ü¶¨ÐÄ
1. ȨÍþÈϿɣº¼ì²âÒªÁì×ñÕÕ¡¶µÚ4°æÌìÏÂÁÙ´²Ä¥Á·±ê×¼²Ù×÷¹æ³Ì¡·£¬£¬£¬£¬£¬£¬Ð§¹û»ñCNASÈϿɣ»£»£»£»£»£»£»
2. ±ã½ÝÌåÑ飺²¿·ÖÏîÄ¿ÎÞÐè¿Õ¸¹£¬£¬£¬£¬£¬£¬²¿·ÖÏîÄ¿2¸öÊÂÇéÈÕ³öµç×Ó±¨¸æ£»£»£»£»£»£»£»
3. רҵ½â¶Á£ºÓɸβ¡¿ÆÒ½Ê¦¡¢Ä¥Á·×¨¼ÒÍŽá½â¶Á£¬£¬£¬£¬£¬£¬ÌṩÒûʳµ÷½â¡¢Ô˶¯¼Æ»®¡¢ÓÃÒ©½¨ÒéµÈ¸öÐÔ»¯Ö¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£
Ըÿһ·Ý¡°Ä¬È»µÄÖ§¸¶¡±£¬£¬£¬£¬£¬£¬¶¼±»Íû¼ûÓëÉÆ´ý¡£¡£¡£¡£¡£¡£¡£¡£ÈÃÎÒÃÇ´Ó½ñÌìÆð£¬£¬£¬£¬£¬£¬Í¨¹ý¡°¿ÆÑ§¼ì²â+¿µ½¡ÉúÑÄ¡±ÊØ»¤¸ÎÔ࣬£¬£¬£¬£¬£¬ÈÃ×Ô¼ºÔ¶Àë¸ÎÓ²»¯¡¢¸Î°©µÄÍþв¡£¡£¡£¡£¡£¡£¡£¡£

¸ÎÓ²»¯¡¢¸Î°©Ïà¹Ø¼ì²âÏîÄ¿¼°ÁÙ´²Ó¦ÓÃ
²Î¿¼ÎÄÏ×
[1] Medicine LibreTexts.22.7E: Liver Function[EB/OL].[2025-10-15].
[2] Ĭɳ¶«ÕïÁÆÊÖ²áרҵ°æ¡£¡£¡£¡£¡£¡£¡£¡£¸ÎÔàµÄ½á¹¹ºÍ¹¦Ð§ [EB/OL].[2025-08-01].
[3] ÖлªÒ½Ñ§»áÍâ¿ÆÑ§·Ö»á¸ÎÔàÍâ¿ÆÑ§×飬£¬£¬£¬£¬£¬ÖйúҽʦлáÍâ¿ÆÒ½Ê¦·Ö»á¸ÎÔàÍâ¿ÆÒ½Ê¦Î¯Ô±»á¡£¡£¡£¡£¡£¡£¡£¡£Î§ÊÖÊõÆÚ¸ÎÔà´¢±¸¹¦Ð§ÆÀ¹Àר¼Ò¹²Ê¶£¨2025 °æ£©[J]. ÖлªÍâ¿ÆÔÓÖ¾£¬£¬£¬£¬£¬£¬2025, 63 (10): 751-760.
[4] ÖйúÖÐÎ÷ҽ͎áѧ»áÏû»¯ÏµÍ³¼²²¡×¨ÒµÎ¯Ô±»á.·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡ÖÐÎ÷ҽ͎áÕïÁÆ×¨¼Ò¹²Ê¶(2025Äê)[J].ÖйúÖÐÎ÷ҽ͎áÏû»¯ÔÓÖ¾,2025,33(04):339-350.
[5] WHO. Global Hepatitis Report 2024 1st ed. Geneva: World Health Organization; 2024.
[6] Zhou J, Zhou F, Wang W et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020 May;71(5):1851-1864.
[7] ·¶½¨¸ß,ÐìСԪ,ÄÏÔÂÃô,µÈ.´úлÏà¹Ø(·Ç¾Æ¾«ÐÔ)Ö¬·¾ÐԸβ¡·ÀÖÎÖ¸ÄÏ(2024Äê°æ)[J].ÊÊÓøÎÔಡÔÓÖ¾,2024,27(04):494-510.
[8] Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016 Jun;17(6):510-9.
[9] Ye P, Gao L, Xia Z, et al. Association between non-alcoholic fatty liver disease and metabolic abnormalities in children with different weight statuses. Public Health. 2024 Oct; 235:160-166.
[10] Zhang L, You W, Zhang H, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015 May;30(5):821-9.
[11] WebMD. Symptoms of Liver Problems[EB/OL]. https://www.webmd.com/digestive-disorders/ss/slideshow-symptoms-liver-problems, 2025-06-09.
[12] Man S, Deng Y, Ma Y, et al. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. Gastroenterology. 2023 Oct;165(4):1025-1040.
[13] Ë︣¹ã,Èνø.·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡Õï¶ÏÒªÁìÑо¿Ï£Íû[J].ÉúÃü¿ÆÑ§,2023,35(10):1348-1357.
[14] ºÂ¿íæ·.Éú»¯Ä¥Á·Öиι¦Ð§Ö¸±ê¼ì²âÔÚ¸ÎÓ²»¯»¼ÕßÖеÄÕï¶Ï¼ÛÖµ[J].ÊÊÓÃÄ¥Á·Ò½Ê¦ÔÓÖ¾,2024,16(01):40-43.
[15] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5.
[16] Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ¡Ý 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015 Apr;60(4):1024-30.
[17] ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á. ¸ÎÓ²»¯ÁÙ´²ÕïÖιÜÀíÖ¸ÄÏ£¨2025 °æ£©[J]. Öлª¸ÎÔಡÔÓÖ¾,2025,33(10)£º958-976.